News Focus
News Focus
Followers 54
Posts 17531
Boards Moderated 0
Alias Born 07/12/2002

Re: Paul A post# 299719

Wednesday, 09/22/2004 3:51:33 PM

Wednesday, September 22, 2004 3:51:33 PM

Post# of 704047
PAUL A: found this in a filing on that comp
again i dont know this comp.....but there are some flags here

The analysis of the data from our Phase 3 trial of Riquent showed that the trial did not reach statistical significance with respect to its primary endpoint, time to renal flare, or with respect to the secondary endpoint, time to treatment with high-dose corticosteroids or cyclophosphamide. Although our NDA for Riquent has been accepted for review by the FDA, the results from our clinical trials of Riquent may not ultimately be sufficient to obtain regulatory clearance to market Riquent either in the United States or Europe, and we may be required to conduct additional clinical studies to demonstrate the safety and efficacy of Riquent in order to obtain marketing approval. There is no guarantee, however, that we will have the necessary resources to complete any additional trial or that any additional trial will sufficiently demonstrate the safety and efficacy of Riquent. Our blood test to measure the binding affinity for Riquent is experimental, has not been validated by independent laboratories and will likely be reviewed as part of the Riquent approval process


Who here wants to comfort the parents of the soldiers below?
4005 brave American soldiers killed..sent to their death by a cowardly president called bush and the opposition that enabled it.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today